Patents Assigned to Merck
  • Patent number: 4710504
    Abstract: Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective .alpha..sub.2 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, ocular antihypertensives, antidiabetics, platelet aggregation inhibitors, antiobesity agents, and modifiers of gastrointestinal motility.
    Type: Grant
    Filed: April 4, 1986
    Date of Patent: December 1, 1987
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Joel R. Huff, Joseph P. Vacca, Steven D. Young, Jane deSolms, James P. Guare, Jr.
  • Patent number: 4710315
    Abstract: Anisotropic compounds of the formula (1) specified in claim 1 are suitable, owing to their low .DELTA..epsilon./.epsilon..perp. values for liquid crystal displays which have high information densities of for examples up to 10.sup.6 image dots and accordingly need to be highly multiplexible; compared with known compounds they offer improved application properties and are relatively simple to synthesize.
    Type: Grant
    Filed: December 16, 1985
    Date of Patent: December 1, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Hans P. Schad, Stephen M. Kelly
  • Patent number: 4710469
    Abstract: A glycoprotein phosphotyrosyl protein phosphatase is isolated from human tissues, such as human placental membrane. Upon membrane solubilization and extraction of the enzyme it was subjected to chromatographic purification and isolation. The analytical and biological responses of the enzyme demonstrate that it is novel and readily distinguished from other enzymes previously isolated from similar tissues. The enzyme is a dephosphorylation enzyme of membrane phosphoprotein kinases, and as such has utility as an antidiabetic agent, an antiatherosclerosis agent or an antitumor agent since certain membrane receptor kinases involved in each such biological function involve a phosphorylation mechanism for cell transformation, metabolism and growth and which, when blocked by the instant enzyme, results in a suppression or alteration of the biological function.
    Type: Grant
    Filed: May 2, 1986
    Date of Patent: December 1, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Theming Liang, Eve E. Slater
  • Patent number: 4710289
    Abstract: The application relates to a precolumn for a chromatography column in cartridge from which is packed with a sorbent and has been provided with frit and sealing elements, the precolumn being composed of an outer holder and, emplaceable therein, an inner sorbent-packed column ring.
    Type: Grant
    Filed: February 27, 1987
    Date of Patent: December 1, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Stefan Wermuth, Gunter Hauke, Klaus Kreher
  • Patent number: 4710513
    Abstract: 6-Phenyl-, phenylalkyl- and phenylethenyl-4-hydroxytetrahydropyran-2-ones in the 4(R)-trans stereoisomeric forms are potent inhibitors of cholesterol synthesis by virtue of their ability to inhibit the enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Type: Grant
    Filed: March 14, 1984
    Date of Patent: December 1, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Alvin K. Willard, Frederick C. Novello, William F. Hoffman, Edward J. Cragoe, Jr.
  • Patent number: 4709837
    Abstract: The present application discloses an improved filter assembly used in a dry powder filling machine in which the bottom of the cylindrical measuring cavity for the powder being measured is formed by the improved filter assembly having a cup shaped recess wherein the floor of the recess contains evenly spaced and relatively small apertures. The aperture-containing floor is backed by a screen which allows vacuum to be applied to draw powder into the cavity but which prevents passage of the powder through the screen while the cavity is being filled. Application of gas pressure to the underside of the floor of the cavity expels the measured powder into a container as a discrete slug with relatively little separation.
    Type: Grant
    Filed: May 1, 1984
    Date of Patent: December 1, 1987
    Assignee: Merck & Co., Inc.
    Inventor: George R. Erdman
  • Patent number: 4709035
    Abstract: 2,6-Disubstituted derivatives of 3-nitropyrazine are disclosed to have activity in increasing the sensitivity of tumor cells to radiation. Also disclosed are methods of preparing such compounds and pharmaceutical compositions including such compounds.
    Type: Grant
    Filed: September 4, 1984
    Date of Patent: November 24, 1987
    Assignee: Merck & Co., Inc.
    Inventor: George D. Hartman
  • Patent number: 4709010
    Abstract: New peptides of the formula IX--Z--NH--CHR--CHOH--CH.sub.2 --CO--NH--CHR.sup.1 --CH.sub.2 --NH--CHY--C.sub.n H.sub.2n --R.sup.2 Iin whichX is H, R.sup.3 --O--CH.sub.2 --CO--, R.sup.3 --O--CO--, R.sup.3 --CH.sub.2 --O--CO-- or R.sup.3 --C.sub.m H.sub.2m --CO--,Z is 1 to 4 aminoacid residues which are bonded together in the manner of peptides and are selected from the group comprising Abu, Ala, Arg, Asn, Dab, Gln, Gly, His, Ile, Leu, Lys, Met, NLeu, Orn, Phe, Pro, Trp, Tyr and Val,is A, Ar-alkyl (in which the group -alkyl contains 1-4 C atoms) or cycloalkyl-alkyl having 4-11 C atoms,R.sup.1 is H or A,Y is H, A, --C.sub.p H.sub.2p --OR.sup.4, --C.sub.p H.sub.2p --NHR.sup.4, --COOR.sup.4, --CONHR.sup.4 or --CONA.sub.2,R.sup.2 is A, cycloalkyl having 3-7 C atoms, Ar, pyridyl, indolyl, imidazolyl, piperidyl, N-benzylpiperidyl or piperazinyl,R.sup.3 is A, cycloalkyl having 3-7 C atoms or Ar,R.sup.
    Type: Grant
    Filed: October 18, 1985
    Date of Patent: November 24, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Gunter Holzemann, Peter Raddatz, Alfred Jonczyk, Claus J. Schmitges
  • Patent number: 4707542
    Abstract: The surface antigen protein of human Hepatitis B virus is synthesized in Saccharomyces cerevisiae as a 23,000-26,000 dalton polypeptide, essentially free of intermolecular disulfide bonds. This antigen is a poor immunogen in animals and man. No prior precedent or method exists for efficiently converting the non-disulfide bonded antigen to a fully intermolecular disulfide bonded particle. We describe the first example of such a conversion in vitro and show that the act of this conversion enhances the immunogenicity of the antigen about 10-fold. The in vitro conversion makes practical the production of hepatitis B surface antigen from microorganisms using recombinant DNA methods.
    Type: Grant
    Filed: August 1, 1984
    Date of Patent: November 17, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Arthur Friedman, E. Dale Lehman, William J. McAleer, Ted F. Schaefer, Edward M. Scolnick, D. Eugene Wampler
  • Patent number: 4707547
    Abstract: Disclosed are 6- and 6,6-disubstituted-3-substituted amino-1-azabicyclo[3.2.0]hept-2-en-7-one-2-carboxylic acids (I): ##STR1## wherein R.sup.1 and R.sup.2 are, inter alia, independently selected from the group consisting of hydrogen, substituted and unsubstituted: alkyl, aryl, and aralkyl; and R' and R" are independently selected from the group consisting of: H, substituted and unsubstituted alkyl and aralkyl, or together form a substituted or unsubstituted cyclic group.Such compounds and their pharmaceutically acceptable salt, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds and methods of treatment comprising administering compounds and compositions when an antibiotic effect is indicated.
    Type: Grant
    Filed: May 2, 1986
    Date of Patent: November 17, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Burton G. Christensen, Ronald W. Ratcliffe
  • Patent number: 4707295
    Abstract: Bicyclooctane derivatives of the formula IR.sup.1 --A.sup.1 --A.sup.2 --R.sup.2 IwhereinR.sup.1 and R.sup.2 independently of one another are each an alkyl group which has 1-12 C atoms and in which it is also possible for one or two non-adjacent CH.sub.2 groups to be replaced by O atoms and/or CO groups and/or --O13 CO groups and/or --CO--O groups and/or --CH.dbd.CH-- groups, one of the radicals R.sup.1 and R.sup.2 being also --A.sup.3 --R.sup.3,A.sup.1 is a 1,4-cyclohexylene group which is unsubstituted or substituted in the 1-position and/or 2-position and/or 3-position and/or 4-position by alkyl which has in each case 1-5 C atoms and is unsubstituted or substituted or fluorinated, and in which it is also possible for one or two non-adjacent CH.sub.2 groups to be replaced by one or two different groupings from the group --O--, --CO--, --CH.dbd.CH--, --S--, --SO-- or --SO.sub.2 --, or is substituted by F, Cl, Br, CN and/or CHO,A.sup.2 is a 1,4-bicyclo[2.2.2] octylene group,--A.sup.3 --R.sup.3 is --Cy--R.sup.
    Type: Grant
    Filed: March 24, 1986
    Date of Patent: November 17, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Ludwig Pohl, Bernhard Scheuble, Andreas Wachtler, Reinhard Hittich, Peter Fuss
  • Patent number: 4705892
    Abstract: An improved process for preparing .alpha.,.omega.-diamino acids, such as D,L-homolysine, 2,8-diaminooctanoic acid, ornithine, lysine, or the like, comprising reaction of phthalic anhydride and an amino alcohol in a hydrocarbon solvent; treatment of the resulting phthalimide--N--(CH.sub.2).sub.n --OH derivative, without isolation thereof, with phosphorus tribromide or phosphorous pentachloride; alkylation of diethyl acetamidomalonate with the phthalimide--N--(CH.sub.2).sub.n --chloride or --bromide of the previous step, in the presence of, particularly, sodium hydride/dimethylformamide; standard acid hydrolysis and decarboxylation; selective protection via copper(II) chelation, N-specific acylation with benzyl chloroformate, and decomposition of the amino acid-copper(II) complex with alkaline thioacetamide; standard t-butoxycarbonyl acylation; and deprotection to obtain the desired .alpha.,.omega.-diamino acids.
    Type: Grant
    Filed: October 16, 1986
    Date of Patent: November 10, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Joshua S. Boger, Linda S. Payne
  • Patent number: 4704227
    Abstract: Compounds of the formula IR.sup.1 --A.sup.1 --Z.sup.1 --A.sup.2 --R.sup.2 IwhereinR.sup.1 and R.sup.2 are each H, an alkyl, alkoxy, alkanoyl, alkanoyloxy or alkoxycarbonyl group with in each case 1-10 C atoms, F, Cl, Br, CN or R.sup.3 --A.sup.3 --Z.sup.2 --,A.sup.1 is --A--, --A.sup.4 --A--or --A--A.sup.4 --,A is a 1,3-dioxane-2,5-diyl or a 1,3-dithiane-2,5-diyl group,A.sup.2, A.sup.3 are each a 1,4-cyclohexylene, 1,3-dioxane-2,5-diyl,and A.sup.4 1,3-dithiane-2,5-diyl, piperidine-1,4-diyl or 1,4-bicyclo(2,2,2)octylene group, or a 1,4-phenylene, pyrimidine-2,5-diyl or pyridazine-3,6-diyl group which is unsubstituted or substituted by one or two F and/or Cl atoms and/or CH.sub.3 groups and/or CN groups,Z.sup.1 and Z.sup.2 are each --CO--O--, --O--CO--, --CH.sub.2 CH.sub.2 --, --OCH.sub.2 --, --CH.sub.2 O or a single bond andR.sup.3 is H, an alkyl, alkoxy, alkanoyl, alkanoyloxy or alkoxycarbonyl group with in each case 1-10 C atoms, F, Cl, Br or CN, with the proviso that(a) at least one group A.sup.2, A.sup.
    Type: Grant
    Filed: February 15, 1985
    Date of Patent: November 3, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Joachim Krause, Andreas Wachtler, Reinhard Hittich, Georg Weber, Bernhard Scheuble
  • Patent number: 4704462
    Abstract: Substituted 2,3,3a,6-tetrahydro-6-oxobenzofuran derivatives have been prepared. These neolignans are found to have potent and specific PAF (Platelet-Activating-Factor) antagonistic activities and thereby useful in the treatment of various diseases or disorders mediated by PAF, for example, pain, fever, inflammation, cardiovascular disorder, asthma, lung edema, allergic disorders, skin diseases, psoriasis, toxic shock syndrome and adult respiratory distress syndrome.
    Type: Grant
    Filed: August 22, 1985
    Date of Patent: November 3, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Michael N. Chang, San-Bao Hwang, Mitree M. Ponpipom, Robert L. Bugianesi
  • Patent number: 4704400
    Abstract: Medicarpin derivatives and related pharmaceutical compositions and methods of treatment are disclosed. The compounds are useful as inhibitors of mammalian leukotriene biosynthesis. As such, they are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders and inflammation.
    Type: Grant
    Filed: June 24, 1986
    Date of Patent: November 3, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Douglas K. Miller, Henry Joshua, Sharon J. Sadowski
  • Patent number: 4704472
    Abstract: A process for direct preparation of an enantiomer of a substituted fluorenyloxyacetic acid is disclosed. The acetic acid derivative is useful for treating brain edema.
    Type: Grant
    Filed: December 18, 1985
    Date of Patent: November 3, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Robin S. E. Conn, Sandor Karady
  • Patent number: 4704405
    Abstract: A water-soluble combination of sodium sulindac and an appropriate base, for example, tromethamine or sodium bicarbonate, has been found to exhibit unexpectedly improved onset of activity relative to conventional water-soluble formulations containing sodium sulindac.
    Type: Grant
    Filed: August 25, 1986
    Date of Patent: November 3, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Joseph L. O'Neill, Eugene J. Dehner
  • Patent number: 4703034
    Abstract: There is disclosed a series of novel cyclic tetrapeptides related to somatostatin. The compounds have surprisingly been found to have the activity of increasing blood glucose when administered. The compounds are prepared using the solid phase or mixed anhydride synthesis methods and compositions and methods utilizing the novel compounds are also disclosed.
    Type: Grant
    Filed: April 28, 1986
    Date of Patent: October 27, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Roger Freidinger, Ruth F. Nutt, Terry A. Lyle, Richard Saperstein
  • Patent number: 4703009
    Abstract: Novel plasmid pVE1, deletion mutants thereof, recombinant derivatives thereof, which is the same as the genome or nucleic acid of such plasmids and derivatives of such genome, which are useful as recombinant DNA cloning vectors into host organisms, such as bacteria, for example, Streptomyces avermitilis; portions of such plasmid genome are additionally useful as adjuncts in recombinant DNA cloning procedures, for examples: 1. to permit the maintenance of cloned DNA in the host, either in an integrated state or as an autonomous element; 2. to serve as promoters for increasing expression of endogenous or foreign genes wherein said promoters are ligated to such genes or otherwise serve as promoters; and 3.
    Type: Grant
    Filed: December 4, 1985
    Date of Patent: October 27, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Tanya MacNeil, Patrice H. Gibbons
  • Patent number: 4702562
    Abstract: Nematic liquid crystal phases containing at least one liquid-crystalline compound, which exhibits at least one discotic phase, are suitable for electro-optic display elements with high multiplexing rates.
    Type: Grant
    Filed: January 17, 1985
    Date of Patent: October 27, 1987
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Bernhard Scheuble, Rudolf Eidenschink, Georg Weber